Sharp Debate Over HIV Vaccine Failure
Scientists Can't Agree on Future of HIV Research
WebMD News Archive
March 25, 2008 -- The recent failure of the most promising HIV
vaccine ever developed has scientists taking stock and wondering where to go
After more than 20 years of research, answers to that question are
"We have to admit to ourselves that we don't know how to make an HIV
vaccine right now," said Beatrice H. Hahn, MD, a microbiologist at the
University of Alabama at Birmingham.
Hahn spoke in front of hundreds of researchers gathered in Bethesda, Md., to
try to brainstorm ideas for finding a vaccine for HIV; the virus has killed 25
million people worldwide and now infects an estimated 33 million, according the
World Health Organization.
The meeting comes several months after the drug company Merck announced it
was halting human trials of its experimental HIV vaccine. Not only did the
vaccine not work to prevent infection, but it also didn't reduce the amount of
virus in people who became infected; there were also indications suggesting it
may have made it easier for some people to contract the virus.
The failure has researchers and policy makers locked in a debate. Some are
calling for more money for testing vaccines similar to the failed Merck vaccine
already in the pipeline. Others want to abandon the vaccines under testing and
start from scratch.
"Nothing currently around is going to cause significant protection, in
the opinion of many of us," Hahn said. She counts herself among the leading
scientists calling on the National Institutes of Health (NIH) to sharply reduce
support for testing existing experimental vaccines. The money should be spent
instead on basic scientific research aimed at finding new approaches to a
vaccine, these scientists say.
Funding HIV Research
NIH officials say they've been hurt by five years of flat funding from
Congress. One effect of the shortfall is dwindling support for young
researchers who could come up with new ideas, they say.
"The easy things have been done," said James Hoxie, MD, who directs
the Penn Center for AIDS Research at the University of Pennsylvania.
Wednesday's meeting was part scientific strategy session, part group therapy
session for a field stunned by its lack of progress.